Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

On Wednesday, 2Seventy Bio Inc (TSVT) stock saw a decline, ending the day at $4.32 which represents a decrease of $-0.45 or -9.43% from the prior close of $4.77. The stock opened at $4.32 and touched ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...

Wegovy is approved for obesity but is also under investigation in a range of other indications. Image credit: Shutterstock / KK Stock. Novo Nordisk’s Wegovy has shown promising benefits in treating a ...

This news brief covers various health-related updates including Washington state's abortion pill stockpile, EPA regulations on fluoridated water, radiation exposure in spaceflight, BioAge Labs' IPO, ...

NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...

KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...

The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy ...